To illustrate the role of Rezūm convective water vapor ablation for treatment of lower urinary tract symptoms secondary to BPH.
A prospective registry was established for Rezūm therapy in Canada at two high-volume centers. All patients had baseline medical and BPH history documented, along with uroflowmetry and validated questionnaires up to 12 months post-surgery.
229 patients (mean age 67.3 years), including 83 with prostate volumes ≥ 80 mL, were treated from April 2019 to December 2020. The mean prostate volume was 71.5mL (range 20-160mL) and 55% had a median lobe. The mean number of injections was 11 (range: 4-28) and mean procedural length was 4.8 minutes (range: 1.5-14). The mean duration of post-procedure catheterization was 9.8 days. IPSS scores improved from baseline by 29%, 53%, and 59% at 1, 3, and 12 months, respectively. IPSS QoL improved from baseline by 30%, 50%, and 67% at 1, 3, and 12 months, respectively. Qmax improved by 60% at 3 months and 74% at 12 months. PVR improved by 51% and 61% at 3 and 12 months, respectively. No statistically significant changes were seen in IIEF-15 or MSHQ-EjD scores. No Clavien-Dindo events ≥ Grade III occurred.
Rezūm therapy is a safe, effective, and quick outpatient procedure for prostate glands over a wide range of volumes. Clinically significant improvements are seen in all validated questionnaires. Objective maximum flow measures improved, while erectile and ejaculatory function remains preserved.

Copyright © 2022. Published by Elsevier Inc.

Author